YMAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YMAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Y-mAbs Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $100.99 Mil. Y-mAbs Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $127.87 Mil. Therefore, Y-mAbs Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.79.
The historical rank and industry rank for Y-mAbs Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 8 years, the highest Equity to Asset Ratio of Y-mAbs Therapeutics was 0.93. The lowest was 0.70. And the median was 0.82.
The historical data trend for Y-mAbs Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.92 | 0.80 | 0.85 | 0.77 | 0.79 |
Y-mAbs Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.77 | 0.79 | 0.79 | 0.78 | 0.79 |
For the Biotechnology subindustry, Y-mAbs Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Y-mAbs Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 100.985 | / | 127.869 | |
= | 0.79 |
Y-mAbs Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 100.985 | / | 127.869 | |
= | 0.79 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics (NAS:YMAB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Gad | director, officer: President and Chairman | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Biotech Aps Wg | 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Johan Wedell-wedellsborg | director, 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Michael J Rossi | director, officer: President & CEO | 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Vignesh Rajah | officer: SVP and CMO | HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950 |
Bo Kruse | director, officer: EVP, CFO, Secy & Treas. | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Susan Laura Smith | officer: Senior Vice President, CCO | 5 OVERLOOK CT, LAMBERTVILLE NJ 08530 |
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Juan Moller San Pedro Claus | director, officer: Chief Executive Officer | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Mahiuddin Ahmed | officer: Sr. VP and CSO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Philip Karl Herman | officer: Sr. VP and CCO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Gregory S Raskin | director | C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
From GuruFocus
By sperokesalga sperokesalga • 05-23-2023
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 10-17-2023
By Marketwired • 08-01-2023
By PRNewswire PRNewswire • 03-17-2023
By sperokesalga sperokesalga • 04-28-2023
By PRNewswire PRNewswire • 03-20-2023
By sperokesalga sperokesalga • 03-17-2023
By Marketwired • 09-06-2023
By sperokesalga sperokesalga • 05-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.